BB Biotech AG
New innovative drugs and technologies are powering sustainable momentum in the biotech sector
Focus on profitable companies and small and mid-cap companies with strong pipelines
Attractive dividend policy; Dividend payment of 5% p.a.
Investment Focus
ISIN-No. CH0038389992
BB Biotech aims to achieve an average annual double-digit return over the long term, thus outperforming the broad market indices by a significant margin. BB Biotech invests worldwide in fast growing companies developing and marketing innovative biotech drugs.
Indexed performance (as at: 19.04.2024)
Share price: CHF 41.75 (18.04.2024)
NAV: CHF 42.05 (18.04.2024)
Rolling performance (18.04.2024)
| Share Price | NAV | Benchmark | |
| 18.04.2023 - 18.04.2024 | -12.46% | 6.61% | -1.88% |
| 18.04.2022 - 18.04.2023 | -18.90% | -12.15% | -1.20% |
| 16.04.2021 - 18.04.2022 | -15.53% | -20.68% | -11.87% |
| 17.04.2020 - 16.04.2021 | 38.55% | 31.30% | 17.77% |
Annualized performance (18.04.2024)
| Share Price | NAV | Benchmark | |
| 1 year | -12.46% | 6.61% | -1.88% |
| 3 years | -15.63% | -9.41% | -5.10% |
| 5 years | -4.48% | -1.23% | 2.81% |
| 10 years | 9.10% | 8.04% | 6.68% |
| Since Inception p.a. | 10.38% | 10.40% | 8.82% |
Cumulative performance (18.04.2024)
| Share Price | NAV | Benchmark | |
| 1M | -8.51% | -2.72% | -3.96% |
| YTD | 1.98% | 3.71% | 1.06% |
| 1 year | -12.46% | 6.61% | -1.88% |
| 3 years | -40.03% | -25.71% | -14.56% |
| 5 years | -20.50% | -6.02% | 14.86% |
| 10 years | 139.23% | 116.80% | 91.07% |
| Since Inception | 1'918.99% | 1'932.36% | 1'209.19% |
Annual performance
| Share Price | NAV | Benchmark | |
| 2023 | -18.15% | -7.39% | -4.79% |
| 2022 | -24.29% | -11.00% | -9.09% |
| 2021 | 8.34% | -11.45% | 2.98% |
| 2020 | 19.35% | 24.26% | 15.80% |
Facts & Key figures
Investment Focus
BB Biotech actively invests worldwide in fast growing companies developing and marketing innovative biotech drugs. At least 90% of its shareholdings must be in listed companies, while always holding more than 50% of its assets in equity investments. Show moreShow less
Investment suitability & Risk
Low risk
High risk
General Information
| Investment Manager | Bellevue Asset Management AG |
| Custodian | Bank Julius Bär AG |
| Fund Administrator | Bellevue Asset Management AG |
| Auditor | Deloitte AG |
| Launch date | 09.11.1993 |
| Year end closing | 31. Dec |
| Management Fee | 1.10% |
| ISIN number | CH0038389992 |
| Valor number | 3838999 |
| Bloomberg | BION SW Equity |
| WKN | A0NFN3 |
Legal Information
| Legal form | Incorporate company |
| SFDR category | Article 8 |
Key data (31.03.2024, base currency CHF)
| Beta | 1.29 |
| Volatility | 32.10 |
| Tracking error | 14.23 |
| Active share | 84.12 |
| Correlation | 0.92 |
| Sharpe ratio | -0.04 |
| Information ratio | -0.11 |
| Jensen's alpha | -1.59 |
| No. of positions | 30 |
Portfolio as at 31.12.2023
Positions
Market capitalization
Breakdown by sector
Currency
Benefits & Risks
Benefits
- Unique opportunity for European investors to access the global biotech sector, a non-cyclical growth industry that is strongly supported by increasing demand, driven by demographic trends and life style changes.
- New innovative drugs and technologies are powering sustainable momentum in the biotech sector.
- Focus on a diversified portfolio of profitable companies as well as small and midcap companies with strong pipelines.
- Management Team with strong scientific and medical expertise. Renowned Board of Directors.
- Attractive dividend policy; Dividend payment of 5% p.a.
Risks
- BB Biotech actively invests in equities. Equities are subject to strong price fluctuations and so are also exposed to the risk of price losses.
- Biotech equities can be subject to sudden substantial price movements owning to market, sector or company factors.
- BB Biotech invests in foreign currencies, which means a corresponding degree of currency risk against the reference currency.
- The price investors pay or receive, like other listed shares, is determined by supply and demand and may be at a discount or premium to the underlying net asset value of the Company.
- BB Biotech may take a leverage of up to 15%, which may lead to even higher price movements compared to the underlying market.
Review / Outlook
At BB Biotech’s Annual General Meeting on March 21, the shareholders approved all agenda items. Dr. Thomas von Planta, former member of the Board of Directors, was elected as the new Chairman of the Board of Directors, succeeding Dr. Erich Hunziker, who did not stand for re-election. In addition, Camilla Soenderby was elected as a new member of the Board of Directors. The shareholders re-elected the current Board members Dr. Clive Meanwell, Laura Hamill, Dr. Pearl Huang and Prof. Dr. Mads Krogsgaard Thomsen for a further one-year term of office.
We have highlighted some of the latest news from our portfolio companies below.
Esperion Therapeutics (+6.8%, in USD) announced on March 22 that the FDA has approved broad new label expansions for NEXLETOL® tablets and NEXLIZET® tablets based on positive outcomes data that include indications for cardiovascular risk reduction and expanded LDL-C lowering in both primary and secondary prevention patients. In addition, the enhanced labels support the use of NEXLETOL and NEXLIZET either alone or in combination with statins. They also include new indications for primary hyperlipidemia, alone or in combination with a statin, and are the only LDL-C lowering non-statin drugs indicated for primary prevention patients.
Ionis Pharmaceuticals (-4.1 %, in USD) announced on March 13 positive results from a Phase II study of ION224, an investigational antisense inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), previously referred to as nonalcoholic steatohepatitis (NASH). The study met its primary endpoint at both doses (120 mg and 90 mg), achieving liver histologic improvement, and also met the important secondary endpoint of MASH resolution.
Argenx (+3.6%, in USD) announced on March 26 that Japan’s Ministry of Health, Labour and Welfare approved VYVGART (efgartigimod alfa) for intravenous (IV) use in adults with primary immune thrombocytopenia (ITP). ITP is a severe, debilitating autoimmune disease, and ITP patients typically experience a significantly lower quality of life.
Documents
Past performance is not a reliable indicator of future results and can be misleading. Changes in the rate of exchange may have an adverse effect on prices and incomes. All performance figures reflect the reinvestment of dividends and do not take into account the commissions and costs incurred on the issue and redemption of shares, if any. The reference benchmark is used for performance comparison purposes only (dividend reinvested). Show moreShow less
